Health Care Counsel Blog

382 total results. Page 1 of 16.

The Senate Health, Education, Labor, and Pensions Committee recently voted to advance bipartisan legislation, called the Lower Health Care Costs Act (the Act), aimed at, among other things, curbing surprise medical bills. 
The US District Court for the District of Columbia invalidated a final rule pursuant to which pharmaceutical manufacturers would have to disclose the list price of certain drugs on direct-to-consumer ads.
On July 9, 2019, the US Department of Health and Human Services, Office of Inspector General (OIG) released two reports addressing hospice deficiencies and the risks, potential harm, and actual harm those deficiencies posed to hospice beneficiarie. 
On June 18, 2019, the Federal Trade Commission (FTC) hosted a workshop to discuss and analyze the effects of Certificates of Public Advantage (COPAs) and Certificates of Need (CONs) on price and access to health care services, health care innovation, and quality of services.
The US Court of Appeals for the Third Circuit recently confirmed that “anti-assignment” provisions — provisions prohibiting insureds from assigning their rights under a health plan to third parties, including medical providers — are enforceable as long as they are unambiguous.
Long-awaited revisions to the regulations implementing the Stark Law, Anti-Kickback Statute, and Civil Monetary Penalties (CMP) Laws are on their way.
The Determination of Need (DoN) Program of the Massachusetts Department of Public Health (Department) recently signaled its intention to end a decades-long moratorium on new nursing home beds in the Commonwealth with the release of proposed DoN guidelines for approval of new long-term care beds.
Today, the US Supreme Court settled a hotly debated issue under Title VII: Is the statute’s charge-filing requirement jurisdictional? The answer, according to the unanimous Court, is no.
On April 30, 2019, the US Department of Justice Criminal Division (DOJ) issued new guidance expanding upon the specific considerations that federal prosecutors should take into account when evaluating corporate compliance programs in connection with a government investigation.
The Medicaid Services Investment and Accountability Act of 2019 (the Act) became law on April 18, 2019. Of most relevance to pharmaceutical manufacturers are the provisions amending the Medicaid statute concerning the Medicaid Drug Rebate Program (MDRP).
The US Supreme Court ruled in Lamps Plus, Inc., et. al. v. Varela, No 17-988 (April 24, 2019), that class-wide arbitration is not available to parties when the underlying arbitration agreement between them is ambiguous as to whether it was contemplated.